Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 395


The level of activity of the alternative lengthening of telomeres correlates with patient age in IDH-mutant ATRX-loss-of-expression anaplastic astrocytomas.

Grandin N, Pereira B, Cohen C, Billard P, Dehais C, Carpentier C, Idbaih A, Bielle F, Ducray F, Figarella-Branger D, Delattre JY, Sanson M, Lomonte P, Poncet D, Verrelle P, Charbonneau M; POLA network.

Acta Neuropathol Commun. 2019 Nov 9;7(1):175. doi: 10.1186/s40478-019-0833-0.


Molecular Profiling Reclassifies Adult Astroblastoma into Known and Clinically Distinct Tumor Entities with Frequent Mitogen-Activated Protein Kinase Pathway Alterations.

Boisseau W, Euskirchen P, Mokhtari K, Dehais C, Touat M, Hoang-Xuan K, Sanson M, Capelle L, Nouet A, Karachi C, Bielle F, Guégan J, Marie Y, Martin-Duverneuil N, Taillandier L, Rousseau A, Delattre JY, Idbaih A.

Oncologist. 2019 Jul 25. pii: theoncologist.2019-0223. doi: 10.1634/theoncologist.2019-0223. [Epub ahead of print]


Temporary blood-brain barrier disruption by low intensity pulsed ultrasound increases carboplatin delivery and efficacy in preclinical models of glioblastoma.

Dréan A, Lemaire N, Bouchoux G, Goldwirt L, Canney M, Goli L, Bouzidi A, Schmitt C, Guehennec J, Verreault M, Sanson M, Delattre JY, Mokhtari K, Sottilini F, Carpentier A, Idbaih A.

J Neurooncol. 2019 Aug;144(1):33-41. doi: 10.1007/s11060-019-03204-0. Epub 2019 Jun 13.


Safety and Feasibility of Repeated and Transient Blood-Brain Barrier Disruption by Pulsed Ultrasound in Patients with Recurrent Glioblastoma.

Idbaih A, Canney M, Belin L, Desseaux C, Vignot A, Bouchoux G, Asquier N, Law-Ye B, Leclercq D, Bissery A, De Rycke Y, Trosch C, Capelle L, Sanson M, Hoang-Xuan K, Dehais C, Houillier C, Laigle-Donadey F, Mathon B, André A, Lafon C, Chapelon JY, Delattre JY, Carpentier A.

Clin Cancer Res. 2019 Jul 1;25(13):3793-3801. doi: 10.1158/1078-0432.CCR-18-3643. Epub 2019 Mar 19.


Neuro-oncology: A rapidly evolving multidisciplinary speciality.

Idbaih A, Delattre JY.

Presse Med. 2018 Nov - Dec;47(11-12 Pt 2):e185-e186. doi: 10.1016/j.lpm.2018.11.016. No abstract available.


Posterior fossa recurrence of WHO grade II and III supratentorial gliomas.

Terziev R, Petrirena G, Marie Y, Mueller WC, Bielle F, Delattre JY.

Rev Neurol (Paris). 2018 Dec;174(10):705-710. doi: 10.1016/j.neurol.2017.10.018. Epub 2018 Oct 9.


Cognitive impairment and morphological changes after radiation therapy in brain tumors: A review.

Jacob J, Durand T, Feuvret L, Mazeron JJ, Delattre JY, Hoang-Xuan K, Psimaras D, Douzane H, Ribeiro M, Capelle L, Carpentier A, Ricard D, Maingon P.

Radiother Oncol. 2018 Aug;128(2):221-228. doi: 10.1016/j.radonc.2018.05.027. Epub 2018 Jul 2. Review.


Machine Learning for Better Prognostic Stratification and Driver Gene Identification Using Somatic Copy Number Variations in Anaplastic Oligodendroglioma.

Rosenberg S, Ducray F, Alentorn A, Dehais C, Elarouci N, Kamoun A, Marie Y, Tanguy ML, De Reynies A, Mokhtari K, Figarella-Branger D, Delattre JY, Idbaih A; POLA Network.

Oncologist. 2018 Dec;23(12):1500-1510. doi: 10.1634/theoncologist.2017-0495. Epub 2018 Jul 17.


Malignant tumors in autoimmune encephalitis with anti-NMDA receptor antibodies.

Bost C, Chanson E, Picard G, Meyronet D, Mayeur ME, Ducray F, Rogemond V, Psimaras D, Antoine JC, Delattre JY, Desestret V, Honnorat J.

J Neurol. 2018 Oct;265(10):2190-2200. doi: 10.1007/s00415-018-8970-0. Epub 2018 Jul 12.


New insights in radiation-induced leukoencephalopathy: a prospective cross-sectional study.

Bompaire F, Lahutte M, Buffat S, Soussain C, Ardisson AE, Terziev R, Sallansonnet-Froment M, De Greslan T, Edmond S, Saad M, Nioche C, Durand T, Alamowitch S, Xuan KH, Delattre JY, Renard JL, Taillia H, Chargari C, Psimaras D, Ricard D.

Support Care Cancer. 2018 Dec;26(12):4217-4226. doi: 10.1007/s00520-018-4296-9. Epub 2018 Jul 7.


Transcriptomic immune profiling of ovarian cancers in paraneoplastic cerebellar degeneration associated with anti-Yo antibodies.

Vialatte de Pémille C, Berzero G, Small M, Psimaras D, Giry M, Daniau M, Sanson M, Delattre JY, Honnorat J, Desestret V, Alentorn A.

Br J Cancer. 2018 Jul;119(1):105-113. doi: 10.1038/s41416-018-0125-7. Epub 2018 Jun 14.


FGFR1 actionable mutations, molecular specificities, and outcome of adult midline gliomas.

Picca A, Berzero G, Bielle F, Touat M, Savatovsky J, Polivka M, Trisolini E, Meunier S, Schmitt Y, Idbaih A, Hoang-Xuan K, Delattre JY, Mokhtari K, Di Stefano AL, Sanson M.

Neurology. 2018 Jun 5;90(23):e2086-e2094. doi: 10.1212/WNL.0000000000005658. Epub 2018 May 4.



Delattre JY.

Rev Neurol (Paris). 2018 Apr;174(4):181. doi: 10.1016/j.neurol.2018.04.001. No abstract available.


Correction to: ATP binding cassette (ABC) transporters: expression and clinical value in glioblastoma.

Dréan A, Rosenberg S, Lejeune FX, Goli L, Nadaradjane AA, Guehennec J, Schmitt C, Verreault M, Bielle F, Mokhtari K, Sanson M, Carpentier A, Delattre JY, Idbaih A.

J Neurooncol. 2018 Jul;138(3):487. doi: 10.1007/s11060-018-2830-8.


ATP binding cassette (ABC) transporters: expression and clinical value in glioblastoma.

Dréan A, Rosenberg S, Lejeune FX, Goli L, Nadaradjane AA, Guehennec J, Schmitt C, Verreault M, Bielle F, Mokhtari K, Sanson M, Carpentier A, Delattre JY, Idbaih A.

J Neurooncol. 2018 Jul;138(3):479-486. doi: 10.1007/s11060-018-2819-3. Epub 2018 Mar 8. Erratum in: J Neurooncol. 2018 Mar 16;:.


Temozolomide Plus Bevacizumab in Elderly Patients with Newly Diagnosed Glioblastoma and Poor Performance Status: An ANOCEF Phase II Trial (ATAG).

Reyes-Botero G, Cartalat-Carel S, Chinot OL, Barrie M, Taillandier L, Beauchesne P, Catry-Thomas I, Barrière J, Guillamo JS, Fabbro M, Frappaz D, Benouaich-Amiel A, Le Rhun E, Campello C, Tennevet I, Ghiringhelli F, Tanguy ML, Mokhtari K, Honnorat J, Delattre JY.

Oncologist. 2018 May;23(5):524-e44. doi: 10.1634/theoncologist.2017-0689. Epub 2018 Feb 22.


Diffuse gliomas classified by 1p/19q co-deletion, TERT promoter and IDH mutation status are associated with specific genetic risk loci.

Labreche K, Kinnersley B, Berzero G, Di Stefano AL, Rahimian A, Detrait I, Marie Y, Grenier-Boley B, Hoang-Xuan K, Delattre JY, Idbaih A, Houlston RS, Sanson M.

Acta Neuropathol. 2018 May;135(5):743-755. doi: 10.1007/s00401-018-1825-z. Epub 2018 Feb 19.


Enhanced antitumor efficacy of biocompatible magnetosomes for the magnetic hyperthermia treatment of glioblastoma.

Le Fèvre R, Durand-Dubief M, Chebbi I, Mandawala C, Lagroix F, Valet JP, Idbaih A, Adam C, Delattre JY, Schmitt C, Maake C, Guyot F, Alphandéry E.

Theranostics. 2017 Oct 13;7(18):4618-4631. doi: 10.7150/thno.18927. eCollection 2017.


Long-term impact of temozolomide on 1p/19q-codeleted low-grade glioma growth kinetics.

Izquierdo C, Alentorn A, Idbaih A, Simó M, Kaloshi G, Ricard D, Barritault M, Meyronet D, Bruna J, Honnorat J, Delattre JY, Ducray F.

J Neurooncol. 2018 Feb;136(3):533-539. doi: 10.1007/s11060-017-2677-4. Epub 2017 Nov 15.


Brain volumetric analysis and cortical thickness in adults with saccadic intrusions (ocular flutter or opsoclonus-myoclonus syndrome).

Ibáñez-Juliá MJ, Pappa E, Gaymard B, Leclercq D, Hautefort C, Tilikete C, Delattre JY, Hoang-Xuan K, Psimaras D, Alentorn A.

Clin Neurol Neurosurg. 2017 Dec;163:167-172. doi: 10.1016/j.clineuro.2017.10.028. Epub 2017 Oct 31.


Early intravenous immunoglobulin treatment in paraneoplastic neurological syndromes with onconeural antibodies.

Berzero G, Karantoni E, Dehais C, Ducray F, Thomas L, Picard G, Rogemond V, Candelier G, Camdessanché JP, Antoine JC, De Seze J, Liou-Schischmanoff A, Honnorat J, Delattre JY, Psimaras D.

J Neurol Neurosurg Psychiatry. 2018 Jul;89(7):789-792. doi: 10.1136/jnnp-2017-316904. Epub 2017 Oct 30. No abstract available.


Improving diagnosis and management of primary brain tumors.

Delattre JY.

Curr Opin Neurol. 2017 Dec;30(6):639-642. doi: 10.1097/WCO.0000000000000500. No abstract available.


Chains of magnetosomes with controlled endotoxin release and partial tumor occupation induce full destruction of intracranial U87-Luc glioma in mice under the application of an alternating magnetic field.

Alphandéry E, Idbaih A, Adam C, Delattre JY, Schmitt C, Guyot F, Chebbi I.

J Control Release. 2017 Sep 28;262:259-272. doi: 10.1016/j.jconrel.2017.07.020. Epub 2017 Jul 13.


Development of non-pyrogenic magnetosome minerals coated with poly-l-lysine leading to full disappearance of intracranial U87-Luc glioblastoma in 100% of treated mice using magnetic hyperthermia.

Alphandéry E, Idbaih A, Adam C, Delattre JY, Schmitt C, Guyot F, Chebbi I.

Biomaterials. 2017 Oct;141:210-222. doi: 10.1016/j.biomaterials.2017.06.026. Epub 2017 Jun 21.


Same-day genomic and epigenomic diagnosis of brain tumors using real-time nanopore sequencing.

Euskirchen P, Bielle F, Labreche K, Kloosterman WP, Rosenberg S, Daniau M, Schmitt C, Masliah-Planchon J, Bourdeaut F, Dehais C, Marie Y, Delattre JY, Idbaih A.

Acta Neuropathol. 2017 Nov;134(5):691-703. doi: 10.1007/s00401-017-1743-5. Epub 2017 Jun 21.


Autoimmune episodic ataxia in patients with anti-CASPR2 antibody-associated encephalitis.

Joubert B, Gobert F, Thomas L, Saint-Martin M, Desestret V, Convers P, Rogemond V, Picard G, Ducray F, Psimaras D, Antoine JC, Delattre JY, Honnorat J.

Neurol Neuroimmunol Neuroinflamm. 2017 Jun 14;4(4):e371. doi: 10.1212/NXI.0000000000000371. eCollection 2017 Jul.


Genome-wide association study of glioma subtypes identifies specific differences in genetic susceptibility to glioblastoma and non-glioblastoma tumors.

Melin BS, Barnholtz-Sloan JS, Wrensch MR, Johansen C, Il'yasova D, Kinnersley B, Ostrom QT, Labreche K, Chen Y, Armstrong G, Liu Y, Eckel-Passow JE, Decker PA, Labussière M, Idbaih A, Hoang-Xuan K, Di Stefano AL, Mokhtari K, Delattre JY, Broderick P, Galan P, Gousias K, Schramm J, Schoemaker MJ, Fleming SJ, Herms S, Heilmann S, Nöthen MM, Wichmann HE, Schreiber S, Swerdlow A, Lathrop M, Simon M, Sanson M, Andersson U, Rajaraman P, Chanock S, Linet M, Wang Z, Yeager M; GliomaScan Consortium, Wiencke JK, Hansen H, McCoy L, Rice T, Kosel ML, Sicotte H, Amos CI, Bernstein JL, Davis F, Lachance D, Lau C, Merrell RT, Shildkraut J, Ali-Osman F, Sadetzki S, Scheurer M, Shete S, Lai RK, Claus EB, Olson SH, Jenkins RB, Houlston RS, Bondy ML.

Nat Genet. 2017 May;49(5):789-794. doi: 10.1038/ng.3823. Epub 2017 Mar 27.


Interactions between glioma and pregnancy: insight from a 52-case multicenter series.

Peeters S, Pagès M, Gauchotte G, Miquel C, Cartalat-Carel S, Guillamo JS, Capelle L, Delattre JY, Beauchesne P, Debouverie M, Fontaine D, Jouanneau E, Stecken J, Menei P, De Witte O, Colin P, Frappaz D, Lesimple T, Bauchet L, Lopes M, Bozec L, Moyal E, Deroulers C, Varlet P, Zanello M, Chretien F, Oppenheim C, Duffau H, Taillandier L, Pallud J.

J Neurosurg. 2018 Jan;128(1):3-13. doi: 10.3171/2016.10.JNS16710. Epub 2017 Mar 3.


Address from the previous President, January 2017.

Delattre JY.

Rev Neurol (Paris). 2017 Jan - Feb;173(1-2):2-3. doi: 10.1016/j.neurol.2017.01.397. French. No abstract available.


Paraneoplastic cerebellar degeneration associated with anti-ITPR1 antibodies.

Berzero G, Hacohen Y, Komorowski L, Scharf M, Dehais C, Leclercq D, Fourchotte V, Buecher B, Honnorat J, Graus F, Delattre JY, Psimaras D.

Neurol Neuroimmunol Neuroinflamm. 2017 Feb 3;4(2):e326. doi: 10.1212/NXI.0000000000000326. eCollection 2017 Mar. No abstract available.


Characteristics in limbic encephalitis with anti-adenylate kinase 5 autoantibodies.

Do LD, Chanson E, Desestret V, Joubert B, Ducray F, Brugière S, Couté Y, Formaglio M, Rogemond V, Thomas-Antérion C, Borrega L, Laurens B, Tison F, Curot J, De Brouker T, Lebrun-Frenay C, Delattre JY, Antoine JC, Honnorat J.

Neurology. 2017 Feb 7;88(6):514-524. doi: 10.1212/WNL.0000000000003586. Epub 2017 Jan 6.


Analysis of temozolomide resistance in low-grade gliomas using a mechanistic mathematical model.

Ollier E, Mazzocco P, Ricard D, Kaloshi G, Idbaih A, Alentorn A, Psimaras D, Honnorat J, Delattre JY, Grenier E, Ducray F, Samson A.

Fundam Clin Pharmacol. 2017 Jun;31(3):347-358. doi: 10.1111/fcp.12259. Epub 2017 Jan 24.


SMART syndrome: Classic transient symptoms leading to an unusual unfavorable outcome.

Bompaire F, Zinchenko L, Lahutte M, Mokhtari K, Psimaras D, Gaultier C, Monjour A, Delattre JY, Ricard D.

Rev Neurol (Paris). 2017 Jan - Feb;173(1-2):67-73. doi: 10.1016/j.neurol.2016.09.014. Epub 2016 Dec 2.


The multidimensional burden of informal caregivers in primary malignant brain tumor.

Bayen E, Laigle-Donadey F, Prouté M, Hoang-Xuan K, Joël ME, Delattre JY.

Support Care Cancer. 2017 Jan;25(1):245-253. Epub 2016 Sep 13.


Neuroleptic intolerance in patients with anti-NMDAR encephalitis.

Lejuste F, Thomas L, Picard G, Desestret V, Ducray F, Rogemond V, Psimaras D, Antoine JC, Delattre JY, Groc L, Leboyer M, Honnorat J.

Neurol Neuroimmunol Neuroinflamm. 2016 Aug 29;3(5):e280. doi: 10.1212/NXI.0000000000000280. eCollection 2016 Oct.


Prognostic impact of the 2016 WHO classification of diffuse gliomas in the French POLA cohort.

Tabouret E, Nguyen AT, Dehais C, Carpentier C, Ducray F, Idbaih A, Mokhtari K, Jouvet A, Uro-Coste E, Colin C, Chinot O, Loiseau H, Moyal E, Maurage CA, Polivka M, Lechapt-Zalcman E, Desenclos C, Meyronet D, Delattre JY, Figarella-Branger D; For POLA Network.

Acta Neuropathol. 2016 Oct;132(4):625-34. doi: 10.1007/s00401-016-1611-8. Epub 2016 Aug 29.


Multi-omics analysis of primary glioblastoma cell lines shows recapitulation of pivotal molecular features of parental tumors.

Rosenberg S, Verreault M, Schmitt C, Guegan J, Guehennec J, Levasseur C, Marie Y, Bielle F, Mokhtari K, Hoang-Xuan K, Ligon K, Sanson M, Delattre JY, Idbaih A.

Neuro Oncol. 2017 Feb 1;19(2):219-228. doi: 10.1093/neuonc/now160.


Characterization of a Subtype of Autoimmune Encephalitis With Anti-Contactin-Associated Protein-like 2 Antibodies in the Cerebrospinal Fluid, Prominent Limbic Symptoms, and Seizures.

Joubert B, Saint-Martin M, Noraz N, Picard G, Rogemond V, Ducray F, Desestret V, Psimaras D, Delattre JY, Antoine JC, Honnorat J.

JAMA Neurol. 2016 Sep 1;73(9):1115-24. doi: 10.1001/jamaneurol.2016.1585.


Chromosome 17p Homodisomy Is Associated With Better Outcome in 1p19q Non-Codeleted and IDH-Mutated Gliomas.

Labussière M, Rahimian A, Giry M, Boisselier B, Schmitt Y, Polivka M, Mokhtari K, Delattre JY, Idbaih A, Labreche K, Alentorn A, Sanson M.

Oncologist. 2016 Sep;21(9):1131-5. doi: 10.1634/theoncologist.2016-0003. Epub 2016 Jul 8.


Role of irradiation for patients over 80 years old with glioblastoma: a retrospective cohort study.

Bracci S, Laigle-Donadey F, Hitchcock K, Duran-Peña A, Navarro S, Chevalier A, Jacob J, Troussier I, Delattre JY, Mazeron JJ, Hoang-Xuan K, Feuvret L.

J Neurooncol. 2016 Sep;129(2):347-53. doi: 10.1007/s11060-016-2182-1. Epub 2016 Jun 16.


Blood-brain barrier, cytotoxic chemotherapies and glioblastoma.

Dréan A, Goldwirt L, Verreault M, Canney M, Schmitt C, Guehennec J, Delattre JY, Carpentier A, Idbaih A.

Expert Rev Neurother. 2016 Nov;16(11):1285-1300. Epub 2016 Jul 4. Review. Erratum in: Expert Rev Neurother. 2016 Nov;16(11):iv.


Clinical trial of blood-brain barrier disruption by pulsed ultrasound.

Carpentier A, Canney M, Vignot A, Reina V, Beccaria K, Horodyckid C, Karachi C, Leclercq D, Lafon C, Chapelon JY, Capelle L, Cornu P, Sanson M, Hoang-Xuan K, Delattre JY, Idbaih A.

Sci Transl Med. 2016 Jun 15;8(343):343re2. doi: 10.1126/scitranslmed.aaf6086.


Mitotic index, microvascular proliferation, and necrosis define 3 pathological subgroups of prognostic relevance among 1p/19q co-deleted anaplastic oligodendrogliomas.

Figarella-Branger D, Mokhtari K, Dehais C, Carpentier C, Colin C, Jouvet A, Uro-Coste E, Forest F, Maurage CA, Vignaud JM, Polivka M, Lechapt-Zalcman E, Eimer S, Viennet G, Quintin-Roué I, Aubriot-Lorton MH, Diebold MD, Loussouarn D, Lacroix C, Rigau V, Laquerrière A, Vandenbos F, Michalak S, Sevestre H, Peoch M, Labrousse F, Christov C, Kemeny JL, Chenard MP, Chiforeanu D, Ducray F, Idbaih A, Delattre JY; POLA Network.

Neuro Oncol. 2016 Jun;18(6):888-90. doi: 10.1093/neuonc/now085. No abstract available.


Integrated multi-omics analysis of oligodendroglial tumours identifies three subgroups of 1p/19q co-deleted gliomas.

Kamoun A, Idbaih A, Dehais C, Elarouci N, Carpentier C, Letouzé E, Colin C, Mokhtari K, Jouvet A, Uro-Coste E, Martin-Duverneuil N, Sanson M, Delattre JY, Figarella-Branger D, de Reyniès A, Ducray F; POLA network.

Nat Commun. 2016 Apr 19;7:11263. doi: 10.1038/ncomms11263.


Motor cortex and hippocampus are the two main cortical targets in LGI1-antibody encephalitis.

Navarro V, Kas A, Apartis E, Chami L, Rogemond V, Levy P, Psimaras D, Habert MO, Baulac M, Delattre JY, Honnorat J; collaborators.

Brain. 2016 Apr;139(Pt 4):1079-93. doi: 10.1093/brain/aww012. Epub 2016 Mar 5.


Adress from the President, January 2016.

Delattre JY.

Rev Neurol (Paris). 2016 Feb;172(2):107-8. doi: 10.1016/j.neurol.2016.02.002. French. No abstract available.


Prediction of Response to Temozolomide in Low-Grade Glioma Patients Based on Tumor Size Dynamics and Genetic Characteristics.

Mazzocco P, Barthélémy C, Kaloshi G, Lavielle M, Ricard D, Idbaih A, Psimaras D, Renard MA, Alentorn A, Honnorat J, Delattre JY, Ducray F, Ribba B.

CPT Pharmacometrics Syst Pharmacol. 2015 Dec;4(12):728-37. doi: 10.1002/psp4.54. Epub 2015 Oct 10.


Paraneoplastic opsoclonus and cerebellar ataxia related to anti-Ma2 antibody: a case report.

Mélé N, Hautefort C, Toledano A, Delattre JY, Psimaras D.

J Neurol. 2016 Feb;263(2):405-406. doi: 10.1007/s00415-015-8012-0. Epub 2016 Jan 11. No abstract available.


Bevacizumab in late-onset radiation-induced myelopathy.

Psimaras D, Tafani C, Ducray F, Leclercq D, Feuvret L, Delattre JY, Ricard D.

Neurology. 2016 Feb 2;86(5):454-7. doi: 10.1212/WNL.0000000000002345. Epub 2016 Jan 6.


Angiopoietin-2 May Be Involved in the Resistance to Bevacizumab in Recurrent Glioblastoma.

Labussière M, Cheneau C, Prahst C, Gállego Pérez-Larraya J, Farina P, Lombardi G, Mokhtari K, Rahimian A, Delattre JY, Eichmann A, Sanson M.

Cancer Invest. 2016;34(1):39-44. doi: 10.3109/07357907.2015.1088948. Epub 2016 Jan 6. Erratum in: Cancer Invest. 2017 Feb 7;35(2):142.


Supplemental Content

Loading ...
Support Center